TNF and inflammatory bowel disease: Furthermore, Wang and colleagues concluded that integrative transcriptomics delineates cellular and molecular mechanisms associated with clinical efficacy of upadacitinib and risankizmab in IBD subjects who are inadequate responders to TNF inhibitors that hold the potential to optimize clinical responses to therapy [338].